{"id":"https://openalex.org/W2016528543","doi":"https://doi.org/10.1038/clpt.1994.205","title":"Therapy with l-deprenyl (selegiline) and relation to abuse liability*","display_name":"Therapy with l-deprenyl (selegiline) and relation to abuse liability*","publication_year":1994,"publication_date":"1994-12-01","ids":{"openalex":"https://openalex.org/W2016528543","doi":"https://doi.org/10.1038/clpt.1994.205","mag":"2016528543","pmid":"https://pubmed.ncbi.nlm.nih.gov/7995017"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.1994.205","doi":"https://doi.org/10.1038/clpt.1994.205","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.1994.205","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059020389","display_name":"Lon S. S. Schneider","orcid":"https://orcid.org/0000-0002-4636-6150","observed_orcids":["https://orcid.org/0000-0002-4636-6150"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lon S Schneider","raw_affiliation_strings":["Department of Psychiatry, University of Southern California, Los Angeles 90033","Departments of Psychiatry, University of Southern California, Los Angeles","University of Rochester, Rochester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, University of Southern California, Los Angeles 90033","institution_ids":["https://openalex.org/I1174212"]},{"raw_affiliation_string":"Departments of Psychiatry, University of Southern California, Los Angeles","institution_ids":["https://openalex.org/I1174212"]},{"raw_affiliation_string":"University of Rochester, Rochester","institution_ids":["https://openalex.org/I5388228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002451678","display_name":"Pierre N. Tariot","orcid":"https://orcid.org/0000-0002-6058-8032","observed_orcids":["https://orcid.org/0000-0002-6058-8032"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pierre N Tariot","raw_affiliation_strings":["Departments of Psychiatry, University of Southern California, Los Angeles","University of Rochester, Rochester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Psychiatry, University of Southern California, Los Angeles","institution_ids":["https://openalex.org/I1174212"]},{"raw_affiliation_string":"University of Rochester, Rochester","institution_ids":["https://openalex.org/I5388228"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041729163","display_name":"Bonnie S. Goldstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bonnie Goldstein","raw_affiliation_strings":["Departments of Psychiatry, University of Southern California, Los Angeles","University of Rochester, Rochester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Psychiatry, University of Southern California, Los Angeles","institution_ids":["https://openalex.org/I1174212"]},{"raw_affiliation_string":"University of Rochester, Rochester","institution_ids":["https://openalex.org/I5388228"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5059020389"],"corresponding_institution_ids":["https://openalex.org/I1174212","https://openalex.org/I5388228"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":1.8929,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.86666667,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"56","issue":"6 Pt 2","first_page":"750","last_page":"756"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.3903999924659729,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.3903999924659729,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.2904999852180481,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.1582999974489212,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selegiline","display_name":"selegiline","score":0.9990000128746033},{"id":"https://openalex.org/keywords/abuse-potential","display_name":"abuse liability","score":0.9599999785423279},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.7749999761581421},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":1.0},{"id":"https://openalex.org/keywords/cognitive-enhancement","display_name":"cognitive enhancement","score":0.699999988079071},{"id":"https://openalex.org/keywords/nootropics","display_name":"nootropic drugs","score":0.7590000033378601},{"id":"https://openalex.org/keywords/drug-addiction","display_name":"drug addiction","score":0.593999981880188},{"id":"https://openalex.org/keywords/mao-b-inhibitors","display_name":"monoamine oxidase B inhibitors","score":0.8420000076293945}],"concepts":[{"id":"https://openalex.org/C2776134090","wikidata":"https://www.wikidata.org/wiki/Q47495783","display_name":"Selegiline","level":4,"score":0.9124946594238281},{"id":"https://openalex.org/C3018251022","wikidata":"https://www.wikidata.org/wiki/Q3184856","display_name":"Abuse liability","level":3,"score":0.7737289667129517},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5584819912910461},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4777509272098541},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4519209861755371},{"id":"https://openalex.org/C3018481051","wikidata":"https://www.wikidata.org/wiki/Q3184856","display_name":"Drugs of abuse","level":3,"score":0.44270074367523193},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.4324568212032318},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.42845243215560913},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.37257635593414307},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.35463428497314453},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.34522339701652527},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.22461798787117004},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1843332052230835},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012642","descriptor_name":"Selegiline","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012642","descriptor_name":"Selegiline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1038/clpt.1994.205","doi":"https://doi.org/10.1038/clpt.1994.205","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.1994.205","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:7995017","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7995017","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2056639461","https://openalex.org/W2485798160","https://openalex.org/W2066525586","https://openalex.org/W89851913","https://openalex.org/W1990342344","https://openalex.org/W2490610502","https://openalex.org/W2017046100","https://openalex.org/W2151712831","https://openalex.org/W124217558","https://openalex.org/W2184142794"],"abstract_inverted_index":{"This":[0,101],"article":[1],"briefly":[2],"reviews":[3],"the":[4,28,49,86],"clinical":[5],"aspects":[6],"and":[7,22,37,57,88,92,108],"rationale":[8,26],"for":[9,13,27,39,53],"therapy":[10],"with":[11],"l-deprenyl":[12,31,70],"several":[14],"neuropsychiatric":[15],"conditions,":[16],"including":[17],"major":[18],"depression,":[19],"Alzheimer's":[20],"disease,":[21],"Parkinson's":[23],"disease.":[24],"The":[25],"use":[29,59,93],"of":[30,48,51,90,94,97],"in":[32],"these":[33],"conditions":[34],"is":[35,41,45,79,102,111],"discussed,":[36],"evidence":[38,52],"efficacy":[40],"reviewed.":[42],"Lastly,":[43],"there":[44],"a":[46,65],"review":[47],"lack":[50],"l-deprenyl's":[54],"abuse":[55,76,98],"potential":[56],"its":[58],"as":[60,103],"putative":[61],"nonspecific":[62],"cognitive":[63],"enhancer,":[64],"so-called":[66],"\"smart":[67],"drug.\"":[68],"Although":[69],"itself":[71],"appears":[72],"to":[73],"have":[74],"no":[75],"potential,":[77],"it":[78,83],"theoretically":[80],"possible":[81],"that":[82],"might":[84],"potentiate":[85],"actions":[87],"frequency":[89],"dosage":[91],"various":[95],"drugs":[96],"or":[99],"dependence.":[100],"yet":[104],"an":[105],"underresearched":[106],"area,":[107],"more":[109],"work":[110],"required.":[112]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}